APIM Therapeutics is developing a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA1 (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM2 (AlkB homolog 2 PCNA Interacting Motif). These compounds are particularly relevant for the treatment of hyper-proliferative disorders such as cancer.

Our therapeutic candidate, ATX-101, is a first-in class PCNA/APIM PPI blocking compound currently being developed for the treatment of several cancer indications either alone or in combination with selected anti-cancer agents. A snapshot of the drug pipeline of APIM Therapeutics is presented below. The company has recently concluded a phase I, first-in-human study in patients with advanced solid tumors. Currently, two clinical trials are in progress: 

1. A phase Ib study in platinum-sensitive ovarian cancer conducted in Australia, testing ATX-101 in combination with platinum-based chemotherapy. The study has recently been concluded and preliminary results have shown that the tested combination had a favorable safety profile and a high response rate.

2. A phase II study in sarcoma (lipo-, and leiomyosarcoma) conducted as an Investigator Initiated Study by the Columbia University Irving Medical Center, evaluating ATX-101 as monotherapy.

Other indications/combinations are also of further interest for future applications and are currently being planned. 

pipeline overview

For more information on our pipeline, feel free to contact us directly.